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Abstract
Introduction
Probiotics are a complementary and integrative therapy useful in the treatment and prevention of
urogenital infections in women. This study extends the work of researchers who systematically
investigated the scientific literature on probiotics to prevent or treat urogenital infections.

Methods
A systematic review was conducted to determine the efficacy of probiotics for prevention and/or
treatment of urogenital infections in adult women from January 1, 2008, through June 30, 2015. We
searched in CINAHL, MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science,
Dissertations and Theses, and Alt-HealthWatch. After removing duplicates and studies that did not
meet inclusion criteria, 20 studies were reviewed. All included at least one species of Lactobacillus
probiotic as an intervention for treatment or prevention of urogenital infections. Data extracted
included samples, settings, study designs, intervention types, reported outcomes, follow-up periods,
and results. We evaluated all randomized controlled trials for risk of bias and made quality appraisals
on all studies.

Results
Fourteen of the studies focused on bacterial vaginosis (BV), 3 on urinary tract infections (UTIs), 2 on
vulvovaginal candidiasis, and one on human papillomavirus (HPV) as identified on Papanicolaou test.
Studies were heterogeneous in terms of design, intervention, and outcomes. Four studies were of good
quality, 9 of fair, and 7 poor. Probiotic interventions were effective for treatment and prevention of
BV, prevention of recurrences of candidiasis and UTIs, and clearing HPV lesions. No study reported
significant adverse events related to the probiotic intervention.

Discussion
The quality of the studies in this systematic review varied. Although clinical practice recommendations
were limited by the strength of evidence, probiotic interventions were effective in treatment and
prevention of urogenital infections as alternatives or co-treatments. More good quality research is
needed to strengthen the body of evidence needed for application by clinicians.

INTRODUCTION
Urogenital infections present significant problems for women's health care providers. Although
effective antimicrobial treatments are readily available in developed countries, concerns mount about
antibiotic cost, overuse or overexposure, sensitivity, and sequelae, including antibiotic resistance.1 An
integrated approach to preventing recurrences of urogenital infections is desirable to enhance the
health and well-being of women and to decrease the need for repeat doses of antibiotics or other
major interventions.
According to the Centers for Disease Control and Prevention (CDC),2 bacterial vaginosis (BV) is the most
common form of vaginitis in premenopausal women. The vagina is normally a microbial environment
dominated by Lactobacillus bacteria.3 BV is the result of a shift to a mixture of primarily anaerobic
bacterial species.3 The species associated with BV include Gardnerella vaginalis, Ureaplasma, and
Mycoplasma, among others.2 There are several antibiotics recommended and alternative BV treatment

options available with oral or vaginal route options.2 However, recurrences of BV are common and
multifactorial.4
Vulvovaginal candidiasis results from an overgrowth of one or more types of yeast organisms that
inhabit the vaginal mucosa in small numbers, most commonly Candida albicans.3 Symptoms include
external dysuria, pruritus, redness, and floccular vaginal discharge.5 Recurrences are common,
especially in women with risk factors, such as diabetes mellitus or immune system compromise.
However, it is estimated that 75% of women will experience at least one episode of vulvovaginal
candidiasis at some point in their lives.5
Escherichia coli is the organism responsible for the largest proportion of symptomatic and
asymptomatic urinary tract infections (UTIs) in women.6 Ideally, antibiotic treatment is reserved for
symptomatic patients (or asymptomatic pregnant women) in whom the organism grows as a single
isolate of greater than 100,000 (105) colony-forming units (CFUs) on a clean catch midstream urine
culture.6 In clinical practice, confirmatory urine culture is often sent while treatment commences. Use
of antibiotics with low patterns of resistance is recommended for first-line management.6
Human papillomavirus (HPV) is the cause of nearly all abnormal Papanicolaou tests. Low-grade
squamous intraepithelial lesions (LGSILs) are associated with more high-risk forms of HPV. Expression
of HPV is transient. Viral clearance can lead to resolution over a period of several months, resulting in
normal cervical cytology on reexamination.7
Quick Points
•
•

•
•
•

Probiotic lactobacilli are commonly used choices for treating and preventing urogynecologic
infections.
Although clinical practice recommendations were limited by the strength of evidence,
probiotic interventions appear to be effective in treatment and prevention of urogenital
infections as an alternative or co-treatment.
None of the probiotic interventions were associated with serious adverse events.
More well-designed clinical research studies are needed on probiotics used to treat or
prevent urogenital infections in women.
If used as co-treatments, other evidence suggests that antibiotic and probiotic interventions
should be separated by at least 2 to 4 hours to avoid the destruction of the live
microorganisms in the gastrointestinal tract.

There is a clear link between vaginal microflora and urogenital infections. Independent of personal
hygiene, the large varieties of microbes that populate the vagina originate from the gastrointestinal
tract.8 Healthy vaginal microflora is characterized by a dominance of Lactobacillus bacterial species.9,10
A number of scientific investigations have demonstrated that the gastrointestinal and vaginal
microflora can be modified with probiotic supplementation to treat and prevent genitourinary
infections.10 Probiotics are live bacteria that confer a health effect on the host when they are
administered in sufficient amounts.11 Therefore, probiotics used to prevent and treat genitourinary
infections contain Lactobacillus species, since the target is the vaginal microflora. The mechanisms of

action of probiotics include acidification of the mucosal surface, prevention of the adherence of
pathogens, the production of substances such as vitamins and immune modulators, and synergistic
action with the host immune system.10 Some species of Lactobacillus produce hydrogen peroxide,
which further acidifies the vaginal mucosa.10 This property makes Lactobacillus a common probiotic
choice for treating and preventing urogynecologic infections.
Abad and Safdar12 conducted a systematic review of the literature from inception through December
2007 to identify the role of Lactobacillus-containing probiotics in the prevention or treatment of 3
specific urogenital infections: vulvovaginal candidiasis, UTI, and BV. They found evidence for the
benefits of certain Lactobacillus strains (particularly L rhamnosus GR-1 and L reuteri) for prevention
and treatment of recurrent urogenital infection, particularly for BV. They also found limited data on the
use of probiotics for UTI and candidiasis. Since their systematic review, there has been significant
consumer and scientific interest in the use of probiotics. We extended that systematic review with
contemporary scientific literature on probiotics to treat or prevent urogenital infections in adult
women.

METHODS
We conducted literature searches in CINAHL, MEDLINE, Cochrane Central Register of Controlled Trials,
Web of Science, Dissertations and Theses, and Alt-HealthWatch. Search terms included “probiotics,”
“Lactobacillus,” “Bifidobacterium,” and “Saccharomyces” combined with
“urogenital infections,” “vaginitis,” “vaginosis,” “vulvovaginitis,” vulvovaginal candidiasis,” “urinary
tract infections,” “vaginal discharge,” “reproductive tract infections,” “sexually transmitted diseases,”
“papillomavirus infections,” and “urethritis.” Results were limited to quantitative studies on adult
females that tested probiotics to prevent or treat common urogynecologic infections and were
published in English from January 2008 through June 2015. Articles addressing HIV infections, cancer,
major diagnoses such as diabetes mellitus, and women who were pregnant were excluded from the
studies reviewed. The first 3 authors also reviewed reference lists of included articles and subsequent
published reviews that addressed some but not all of our inclusion criteria for relevant papers to
identify additional studies not retrieved through the initial search.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)13 guidelines were
followed throughout the systematic review. The PRISMA Diagram (Figure 1) outlines the process used
to identify, screen, and determine the eligibility of the articles to be analyzed. Of the 40 full-text
articles screened, 20 were excluded with reasons. Twenty studies were included in the final analysis.
These included 14 randomized controlled trials (RCTs),3,14-26 one quasi-experiment,27 2 prospective
cohort studies,28,29 and 3 single-group investigations.30-32

Figure 1. PRISMA Flow Diagram

Data were extracted independently and reviewed by the first 2 authors. Data collected included
samples, settings, study designs, intervention types, reported outcomes, follow-up periods, and
results. Data extraction was verified by comparing data tables. Statistical analysis was not possible
because of the heterogeneity of probiotic preparations, primary and secondary outcomes, and clinical
trial methods. Instead, a detailed quality assessment was made on each study. We adapted an
assessment approach that allowed for a broader evaluation of quality.33 First, the risk of bias was
assessed for the 14 RCTs using the Cochrane Collaboration Risk of Bias of Randomized Controlled Trials
Assessment,34 which includes details about randomization and blinding. The first 2 authors conducted
these evaluations and rated each study as low, unclear, or high risk of bias. 34 Agreement was reached
about any differing ratings. These risk of bias ratings are presented in Table 1. These ratings were
shared with the last 2 authors, who individually evaluated every study on the following additional 3
domains recommended by the Agency for Healthcare Research and Quality (AHRQ) for evaluating
effectiveness: consistency of the findings, directness, and precision.35 The non-RCTs were rated on
only these final 3 domains, while the RCTs were rated on all of the criteria. The last 2 authors reached
consensus on their combined evaluations of each study using both of the quality assessment
approaches noted above. Finally, they rated the study's overall quality as a) “good” (low risk of bias for
RCTs, consistency of results), direct (findings directly attributable to intervention or not), and precise
(repeatability); b) “fair” (variable on these domains); or c) “poor” (high risk of bias for RCTs,
inconsistent, findings indirectly related to the intervention, and imprecise), 33-35 as also shown in Table
1.

Table 1. Summary of Studies of Probiotics by Urogenital Infections
Author
Year
Country

Design
Total N

Risk of Bias
Rating
Overall
Quality
Rating

Intervention
Probiotic Species,
Dose, Route, Duration,
and Follow-up

Medication
Pretreatment
or Cotreatment

Probiotic Intervention Findings
(P values provided if available)

RCT
96

Unclear
Poor

L gasseri LN40
L fermentum LN99
L casei subsp. rhamnosus LN113
Pediococcus acidilactici LN23
108−109 total; vaginal capsules;
5 days; 6 months

Metronidazole or
clotrimazole

↑ colonization with lactic acid
bacteria (P < .0001)
↓symptoms after administration (P
= .03) and after second menses (P =
.04)

RCT
24

Low
Good

Metronidazole

61% of probiotic group colonized
with Lactin-V by day 10 or 28
No significant difference in AE

Mastromarino15
2009
Italy

RCT
34

Unclear
Fair

None

↑ BV cure rate at 2 weeks (P < .05)
↓ Nugent scores (P < .05)

Hemalatha16
2012
India

RCT
149

Low
Fair

Producta containing L crispatus
(CTV-05)
2 × 109; vaginal applicator; 2
weeks; 1 month
Combination productb
containing
L brevis CD2
L salivarius subsp salicinius
L plantarum
Ascorbic acid
Sodium bicarbonate
Acetic acid
Stearic acid
Magnesium stearate
≤ 109; vaginal tablets; 7 days; 3
weeks
Combination productb
containing
L brevis CD2

none

↓ proinflammatory cytokines IL-β
(P < .001), IL-6 (P < .015)

Bacterial Vaginosis
and Vulvovaginal
Candidiasis
Ehrstrom3
2010
Sweden

Bacterial Vaginosis
Hemmerling14
2010
US

Petricevic17
2008
Austria

RCT
190

Unclear
Fair

Larsson18
2008
Norway

RCT
100

Low
Fair

Marcone28
2008
Italy
Martinez19
2009
Brazil

Prospective
cohort
84
RCT
64

NA
Poor

Rossi30
2010
Italy
Ya20
2010
China

Single group
40

NA
Poor

RCT
120

Low
Fair

Unclear
Good

L salivarius subsp. salicinius
L plantarum
Ascorbic acid
Sodium bicarbonate
Acetic acid
Stearic acid
Magnesium stearate
≤ 109; vaginal tablets; 8 days; 9
days
Combination productc
containing
L casei rhamnosus (Lcr35)
3.41 mg Magnesium stearate
109; vaginal capsules; 7 days; 6
weeks
Combination productd
containing
L gasseri (LBa EB01-DSM 14869)
L rhamnosus (LBp PB01-DSM
14870)
108–109; vaginal capsules, 10
days per month for 4 months; 6
months
L rhamnosus
104; vaginal capsules; 4 months;
6 months
L rhamnosus GR-1
L reuteri RC-14
109 each; oral capsules; 28
days; 28 days
L rhamnosuse
106; vaginal tablets; 24 months,
24 months
Combination productf
containing
L rhamnosus A-119
L acidophilus A-212

Clindamycin

Nugent score ↓ by 5 grades (P <
.001)
↓ Mean Nugent score (P < .001)
No significant difference in BV
between groups (P = 0.32)

Metronidazole
(active control
group only)

↑ Time to BV recurrence (P <.027)
No significant difference in BV cure
rate at one month (64% probiotic vs
78% placebo) (P > .05)

Clindamycin

↓ BV recurrences (P = .05)

Metronidazole

↑ BV cure rate (P = .001)
↑ Normal Nugent scores (P = .011)

Tinidazole

↓ pH (P < .001)
Change in pH (P < .02)

none

↓ BV recurrences (P = .001)
↓ Gardnerella at 2 months (P = .02)

Ling29
2013
China

Prospective
cohort
115

NA
Fair

Donders21
2010
Belgium

RCT
46

High
Poor

Bradshaw22
2012
Australia

RCT
450

Unclear
Fair

Vicariotto23
2014
Italy

RCT
35

High
Fair

Single Group
30

NA
Fair

Vulvovaginal
Candidiasis
Vicariotto31
2012
Italy

Streptococcus thermophilis A336
8 × 109; vaginal capsules; 2
months; 11 months
L delbrueckjii subsp. lactis
DM8909
109; vaginal suppositories; 10
days; 1 month
Combination productg
containing
L acidophilus KS400
plus 0.03 mg estriol
107; vaginal suppositories; 10
days; 4 months
Combination productg
containing
L acidophilus KS400
plus 0.03 mg estriol
107; vaginal pessary; 6 days; 6
months
Combination producth
containing
L fermentum LF15 (DSM 26955)
L planetarium LP01 (LMG P21021)
340 mg of arabinogalactana
241 mg of
fructooligosaccharidesa
50 mg tara gumb
4 × 108 each strain; slowrelease vaginal tablet; 28 days; 2
months

Combination producth
containing
L fermentum LF10

Metronidazole
(active control
group only)

↑ BV cure rate at 30 days (P = .013)

Metronidazole
(control group only)

Probiotic treatment efficacy
equivalent to metronidazole at
2 weeks, but less effective than
metronidazole at 1 month.

Metronidazole

No significant difference in BV
recurrence between groups (P = .82)

None

↓ Nugent scores (P < .001)

None

↓ VVC symptoms at 1 month (P <
.001) and at 2 months (P < .001)

Anukam24
2009
Nigeria

RCT
59

High
Poor

Murina32
2012
Italy

Single group
58

NA
Poor

RCT
252

Low
Good

Urinary Tract
Infection
Beerepoot25
2012
Netherlands

L acidophilus LA02
273 mg of arabinogalactani
332 mg of
fructooligosaccharidesi
64 mg citric acid
56 mg of sodium bicarbonatej
4 × 108 each strain; slowrelease vaginal tablet; 28 days; 2
months
L rhamnosus GR-1
Fluconazole
L reuteri RC-14
5 × 109 total; oral capsules; 90
days; 3 months
Combination producth
Fluconazole X3
containing
doses
L fermentum LF-10 (DSM 19187)
L acidophilus LA02 (DSM 21717)
340 mg of arabinogalactani
241 mg of
fructooligosaccharidesi
50 mg tara gum
63 mg citric acid
54 mg sodium bicarbarbonate
4 × 108 each strain; slow-release
vaginal tablet; 28 days; 7
months

L rhamnosus GR-1
L reuteri RC-14
109; oral capsules; 6 months; 15
months

↓ VVC recurrence in 3 of 26 at 2
months (11.5%, P =.083)

No significant impact of probiotic on
VVC treatment at 7 days (P = .149)
↓ VVC recurrences (P < .057)
72% experienced no VVC
reoccurrence in 7 months of followup

Trimethoprim sulfa- No significant difference in UTI
tamethoxazole
reoccurrence between probiotics
and controls
↓ Mean recurrence per year for
uncomplicated UTI (P < .001)
0.4 UTI per year (95% CI, –0.4 to
1.5) was outside 10% noninferiority
margin

Stapleton26
2011
US

Human
Papillomavirus
Verhoeven27
2013
Belgium

RCT
100

Low
Good

Producta containing
L. crispatus (CTV-05)
2 × 109; vaginal capsules; 3
months; 3 months

Unspecified
“standard
treatment”

Decreased antibiotic resistance in
probiotic group (stats not provided)
No significant difference in AEs (OR,
1.0; 95% CI, 0.6-1.6)
Significant difference in L crispatus
colonization in probiotic group (P <
.004)
“High-level colonization with L
crispatus”
↓ UTI recurrence (P < .01)

Probiotic beveragek containing
none
Twice the clearance of HPV lesions
8×109 L casei Shirota per 2.7(P = .05)
ounce bottle
Probiotic group had increased HPV
Dose not stated; oral drink; 6
viral clearance (29%) vs controls
months; 6 months
(19%) (P = .41)
Abbreviations: AE, adverse events; BV, bacterial vaginosis; CFU, colony-forming units; HPV, human papillomavirus; P, probability; L, Lactobacillus; VVC,
vulvovaginal candidiasis; UTI, urinary tract infection.
Notes: aLactin V, Osel, Inc.; Mountain View, CA; bFlorisia, VSL Pharmaceuticals, Inc. Gaithersburg, MD; c Gynophilus, Quamed, Antwep Belgium;
dEcoVag, Bifodan, Hunested, Denmark; eNormagin, Baldacci Laboratories; Pisa, Italy; fProbaclac, Nicar Laboratories, Quebec, Canada; gGynoflor,
Medinova AG, Zurich, Switzerland; hAcidCand 30, Probiotical, Novara, Italy;iprebiotic fiber; jAlthough the ingredients listed vary slightly between the two
publications by Vicariotto,23,31 the use of the same commercially available product was confirmed through personal communication with the primary
author; kYakult, Yakult USA, Fountain Valley, CA.
Quasiexperiment
51

NA
Poor

RESULTS
In this systematic review, we focused on probiotic interventions as treatment and/or prevention of
select urogenital infections in women: BV, candidiasis, UTI, and HPV. In the results section, we report
the findings from the studies reviewed in the following order: a) quality assessment; b) study
characteristics; c) definitions of urogenital infections; d) participant recruitment, inclusion, exclusion,
and study restrictions; e) description of study interventions; f) outcomes by urogenital infection type;
and g) adverse events.

Quality Assessment of Randomized Controlled Trials Reviewed
As shown in Table 1, we evaluated the 14 RCTs according to risk of bias using the Cochrane assessment
criteria34 and determined that 6 (64%) were of good quality with a low risk of bias.14,16,18,20,25,26 Five
RCTs were rated as having an unclear risk of bias,3,15,17,19,22 and the remaining 3 were identified as
having a high risk of bias.21,23,24
The overall quality ratings for the findings of each study reviewed are also presented in Table 1
according to 3 levels within the 3 domains: consistency, directness, and precision. Four studies were
determined to have good quality, 9 were fair, and 7 poor, as indicated in the table. Two groups of
investigators disclosed relationships with a commercial probiotic financial relationship; others either
reported that there was nothing to disclose or did not address the issue. 14,18

Definitions of Urogenital Infections
The urogenital infections were operationally defined in each study. These diagnoses formed part of the
inclusion criteria for participants in the investigations.
Bacterial vaginosis was diagnosed either by Amsel's clinical criteria (3 of 4 of the following:
homogeneous vaginal discharge, pH > 4.5, presence of clue cells, and a positive potassium hydroxide
(KOH) amine (“whiff”) test)36 or Nugent's Score37 (ratings based on a Gram stain smear of vaginal
secretions; a score of ≥ 7 is consistent with BV) or both. Changes in Amsel's criteria and/or Nugent's
scores were used as outcome measure(s) to indicate treatment success. Therefore, all of the studies of
probiotics for prevention or treatment of BV used appropriate diagnostic criteria.
Vulvovaginal candidiasis was defined as the presence of clinical vaginitis (ie, floccular, odorless vaginal
discharge; dyspareunia; dysuria; local irritation) plus evidence of yeast hyphae on microscopic
examination, and it can be confirmed by culture using Saboraud agar.3,24 The condition is associated
with a normal vaginal pH of less than or equal to 4.5; therefore, pH testing is not a useful diagnostic
approach for this condition.5 Lactobacillus colonization is not altered in vulvovaginal candidiasis.3
Two studies focused on probiotics as an intervention to prevent UTIs.25,26 Stapleton recruited
premenopausal-aged women who had current, uncomplicated, symptomatic cystitis.26 This was
defined as one or more of the following: presence of typical UTI symptoms, 8 or more white blood cells
per high-power field on urinalysis, 102 or greater CFUs/mL of a uropathogen as a single organism.

Beerepoot recruited asymptomatic women based on their self-reported history of 3 or more
symptomatic UTIs in the year prior to the study.25
Verhoeven studied the efficacy of probiotics to clear HPV infections.27 A finding of LGSIL on the
participant's latest Papanicolaou test was used as one of the inclusion criteria for the study. Therefore,
in all the studies reviewed, the researchers had used and reported the relevant diagnostic criteria they
followed to determine the presence of the infection they were attempting to prevent and/or treat.

Participant Recruitment, Inclusion, Exclusion, and Study Restrictions
A review of the studies revealed that participants were predominately premenopausal-aged women. In
3 studies, the participants included both pre- and postmenopausal adult women.20,30,31 Beerepoot
recruited exclusively postmenopausal participants for a study of probiotics to prevent UTI recurrence. 25
Ling did not describe participant characteristics such as age.29 In 2 studies, women who had irregular
menses were excluded,18,26 while the timing of menstruation was a consideration in the initiation of
the intervention in 6 studies.3,15,16,18,19,29
Several of the investigators added inclusion criteria or restrictions on sexual behavior and/or
contraception during the study. In 4 of the studies, women were required to be sexually abstinent
during vaginal treatment portions of the study.15,16,22,29 Hemalatha16 specifically recruited sexually
active participants, while Donders21 excluded participants who had unprotected intercourse in the
prior 24 hours. Restrictions on douching and/or vaginal medications were present for participants in
10 investigations.3,15,16,20-23,26,29,31 In 5 of the studies, participants were excluded if they used certain
specified forms of contraception,14,16,17,25,28 while Stapleton26 included participants who agreed to use
contraception.

Description of Study Interventions
This section includes our analysis of the study interventions. It refers to information contained in Table
2. The studies were evaluated for the use of medications prescribed for treatment or prevention of the
urogynecologic infections before or during the clinical trials. These medications included antimicrobial
therapy, antifungals, and estrogen, which are detailed below.

Table 2. Synthesis of Significant Findings
Urogenital
Infection
Bacterial
vaginosis

Studies Included
Goal
Treatment

in Synthesis
Martinez19 Ling29
Mastromarino15

Symptoms

Ehrstrom3

1(95)

Recurrence
rate

Marcone,28 Donders20

2(204)

Recurrence
time

•

Larsson18

1(100)

pH level

•

Rossi30

1(40)

Martinez19 Vicariotto23
Mastromarino15
Petricevic17

4(323)

Nugent
scores

Vulvovaginal
candidiasis

Number
of
Studies
(Na)
3(231)

Symptoms

•
•

Vicariotto31
Ehrstrom3

2(140)

Prevention

•

Anukum24

1(59)

Probiotic Intervention Outcome
Significantly ↑ cure: L rhamnosus and L reuteri19 L
delbrueckii subsp. lactis29 A combination product15
containing L brevis CD2, L salivarius subsp. salicinius
and L plantarum (and other active ingredients)
Significantly ↓ symptoms: L gasseri, L fermentum, L
rhamnosus, and P aciditactici 3
Significantly ↓ the recurrence rate: L rhamnosus28 A
combination product containing L rhamnosus A-119,
L acidophilus A-212, Streptococcus thermophilis A336 20
Significantly ↑time to recurrence: A combination
product18 containing L gasseri (LBa EB01-DSM 14869)
L rhamnosus (LBp PB01-DSM 14870)
Significantly ↓ vaginal pH compared to pH tablet: L
rhamnosus30
Signficantly ↓ Nugent scores: L rhamnosus and L
reuteri19 L fermentum and L planetarum23 A
combination product15 containing L brevis CD2, L
salivarius subsp. salicinius and L plantarum (and
other active ingredients) A combination product17
containing L casei rhamnosus (Lcr35) (and another
active ingredient)
Significantly ↓ symptoms: A combination product
containing L fermentum LF10, L acidophilus LA02, and
other ingredients31 L gasseri, L fermentum, L
rhamnosus, and Pediococcus acidilactici3
Significantly ↓ recurrences: A combination product
containing24 L rhamnosus A-119, L acidophilus A-212,
Streptococcus thermophilis A-336

Strength of Evidenceb
Moderatec; includes 2
RCTs, one of fair and one
of good quality and one
prospective cohort study
of fair quality
Low; includes one RCT of
poor quality
Low, includes one RCT of
poor quality and a
prospective cohort study
of fair quality
Low; includes one RCT of
fair quality
Low; includes one single
group study of poor
quality
Moderate; includes 3
RCTs, 2 with fair and one
with good quality

Low, includes one RCT of
poor quality and one
single group study of fair
quality
Low; includes one RCT of
poor quality

Urinary tract
infection

Prevention

•
•

Beerepoot25
Stapleton26

2(352)

HPV

Lesion
resolution

•

Verhoeven27

1(51)

Significantly ↓ mean annual recurrence: L
rhamnosus and L reuteri25 Significant ↓ in
recurrence: High-level colonization with L crispatus26
Twice the clearance of LGSIL: Ingestion of a milk
product containing L. casei Shirota27

Moderate; includes 2
RCT of good quality

Low; includes one quasiexperiment of poor
quality
Abbreviations: L, Lactobacillus; HPV, human papillomavirus; UTI, urinary tract infection; LGSIL, low-grade squamous intraepithelial lesions.
a
Sample sizes from individual studies are included in more than one probiotic intervention outcome, if applicable.
b
Adapted from strength of evidence used from the Agency for Healthcare Research and Quality Methods Guide.35 Definitions from Likis et al:33
“High: High confidence that the evidence reflects the true effect. Further research is unlikely to change estimates. Moderate: Moderate confidence that
the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low: Low confidence that the evidence reflects the true effect. Further research is likely to change confidence in the estimate of effect and is also likely to
change the estimate.
Insufficient: Evidence is either unavailable or does not permit a conclusion” (p. ES-9).

Antimicrobial Therapy
Antimicrobial therapy varied among studies but was used in most. Among the 14 investigations of BV, 5 used no conventional antibiotic
treatment prior to or during the study intervention.15,16,20,23,31 Eight used antibiotics as a pretreatment prior to randomization,3,14,17-19,22,29,30
while Donders21 treated concurrently with an antibiotic and the probiotic study intervention. Ling conducted a cohort study in which
participants with BV were either treated using metronidazole gel or the vaginal probiotic intervention.29
Antimicrobial interventions varied between the 2 probiotic investigations on UTIs. Stapleton recruited participants with an acute UTI and
randomized them to a placebo or probiotic intervention after all received standard antibiotic treatment. 26 In a noninferiority trial,
Beerepoot compared antimicrobial therapy to a probiotic intervention to suppress UTI recurrences. 25
Antifungal Therapy
Anukam enrolled women with a history of recurrent candidiasis. All participants were randomized following conventional treatment to
either a placebo or probiotic.24 Murina studied the efficacy of a commercially available probiotic product after all participants received 3
doses of fluconazole (Table 2).32
Estriol Therapy
Two of the probiotic interventions for BV included 0.03 mg of vaginal estriol with the probiotic. 21,22 This was a part of one of the
commercially available probiotic combination products noted by Donders only.21 Rationale for the estriol component of the intervention
was not provided. These researchers did not report participants’ use of any other estrogen-containing products.

Selection and Type of Probiotic Interventions
The studies were reviewed to evaluate the type of probiotic interventions used. All of the study interventions included a single or multiple
strain combination of Lactobacillus species (see Table 2). Although multiple species were used, L rhamnosus and L acidophilus were the
most frequently used probiotics. Ya added Streptococcus thermophilis to 2 Lactobacillus strains.20 Ehrstrom used a combination that
included Pediococcus acidilacti that is in the Lactobacillaceae bacterial family.3 Twelve investigations included the use of products
commercially available in their study settings. The ingredients of these commercially available products are detailed in Table 2. Although 3
investigations used the same product, the ingredients varied between articles. 23,31,32 Seven of the interventions contained nonprobiotic
active ingredients.
Several investigators provided a rationale for choice of probiotic(s) species and/or strains that was specific for action against the urogenital
infection studied. Hermmerling conducted preparatory in vitro testing and determined that L crispatus CTV-05 was effective against BV.14
Stapleton chose the same probiotic for its proven efficacy against BV.26 Petrievic used L casei rhamnosus Lcr35 for its 20-year record of
safety and its proven ability to inhibit Gardnerella vaginalis.17 Murina indicated that the choice of product was based on in vitro testing that
demonstrated efficacy on the vaginal microflora without fostering candidial propagation.32 Bradshaw stated that L acidophilus KS400 was
chosen because of prior research that demonstrated efficacy against BV.22 Hemalatha and Ya selected probiotic strains with general
evidence of efficacy against urogenital infections.16,20 Ling referred to in vitro testing for efficacy of L delbrueckii subspecies lactis DM8909
against BV but did not provide a citation.29
Ehrstrom stated that Pediococcus acidilactici LN23 was chosen for BV and candidiasis because it has a shorter generation time compared to
lactobacilli.3 It was hypothesized that this would lead to a rapid decrease in vaginal pH because it would act as starter culture for other
vaginal probiotic bacteria. Vicariotto selected the strain L plantarum LF5 based on in vitro testing that demonstrated its inhibition of
Gardnerella vaginalis.23 Beerepoot used a combination of L rhamnosus GR-1 and L reuteri RC-14, because of evidence of efficacy with
restoration of vaginal flora and to reduce colonization with pathogens.25 Slow release, effervescent vaginal tablets containing citric acid and
sodium bicarbonate were used by Vicariotto and Murina to administer the probiotic. 31,32 Their rationale was that the commercial product
would rapidly (40-60 minutes) create an anaerobic vaginal environment to foster probiotic growth while creating a biofilm to prevent
pathogen adherence.31,32
Dosing
The probiotic dosing was clearly stated in 13 of the 20 studies reviewed (65%) as presented in Table 2. Dosages ranged from 104 to 1010
CFUs. Most investigators reported daily doses between 107 and 109 CFUs for the probiotic interventions. Verhoeven did not provide the
probiotic intervention dose used.27 Beerepoot did not clarify whether the dose provided was for each individual probiotic or if they were

reporting a total of the CFUs in the combination product.25 Several other investigators stated a range of dosing for the probiotics they had
studied but never gave an exact dose.3,15,16,18
Route
Sixteen of the studies used the vaginal route for the probiotic interventions. Of these, 5 used vaginal capsules exclusively, 3,17,18,20,26 8
employed vaginal tablets,15,16,21,23,28,30-32 one a vaginal applicator,14 one vaginal suppositories,29 and one a vaginal pessary.22 Three
investigations used oral capsules for the probiotic intervention.19,24,25 Verhoeven delivered the intervention in a commercially available
probiotic beverage (Table 1).27
Length of Treatment
The duration of the probiotic interventions ranged from 5 days to 12 months, as shown in Table 2. The studies aimed at prevention had
somewhat longer probiotic interventions. Rationale for the duration of treatments was not provided in the studies reviewed.

Outcomes
The evaluation of outcomes was complicated by the variations in probiotic interventions, duration of treatment, and the goals of treatment,
prevention, or both. Significant probiotic related findings of the studies are summarized by urogynecologic infection in Table 2. The efficacy
of the probiotic intervention was evaluated in each study using the diagnostic criteria for the specific infection(s) as described in the study
design (eg, a decreased Nugent score for BV).
Bacterial Vaginosis
An examination of the 14 investigations of probiotics against BV revealed that 8 studies were focused on treatment of BV, 3,14-16,19,21-23 while
6 focused on prevention.17,18,20,28-30 However, some of the treatment-related trials reported outcomes on recurrences. Therefore, the lines
separating treatment and prevention were indistinct.
All of the investigations of probiotics against BV included premenopausal-aged participants. As shown in Table 2, Martinez, Ling, and
Mastromarino all reported a significant increase in BV cure in the probiotic group compared to controls. 15,19,29 Not all of the investigations
use BV cure as their main study outcome. For example, Hemmerling14 measured vaginal colonization with the probiotic bacteria. Rossi30
evaluated pH by using a pH tablet as control and found that the probiotic intervention resulted in both a significant reduction in vaginal pH
compared to controls at measurement points, as well as a significant change in pH from baseline. In 4 studies, a decrease in the Nugent
score was the primary or secondary study outcome.15,17,19,23 Both Marcone28 and Ya20 found that the probiotic interventions reduced BV
recurrence while Larsson18 found that the probiotic intervention significantly reduced the time to BV recurrence. Hemalatha demonstrated
that the probiotic intervention significantly reduced 2 proinflammatory cytokines.16

Vulvovaginal Candidiasis
Among the 3 investigations of probiotics to treat and/or prevent candidiasis, findings were variable, as shown in Table 2. None of the
studies demonstrated that the probiotic interventions were effective in the treatment of acute candidiasis. However, both Anukam 24 and
Vicariotto31 found a significant reduction in recurrences in women who received the probiotic intervention. Ehrstom found that probiotic
bacteria were still detectable at 6 months in 9% of the intervention group.3
Mixed Urogenital Infections
Ehrstrom also explored the impact of a probiotic intervention for women who had either BV or candidiasis or both. 3 The probiotic
intervention significantly increased colonization with lactic acid bacteria and led to significant reductions in symptoms.
Urinary Tract Infections
The 2 double-blind placebo controlled RCTs of probiotics to prevent UTI recurrences were examined for commonalities and differences.25,26
Stapleton (2011) demonstrated that the probiotic intervention significantly increased colonization with L crispatus and this led to a
reduction in UTI recurrence.26 Beerepoot (2013) found that the probiotic intervention did not meet the noninferiority margin, but among
women with uncomplicated UTI, the average number of UTI recurrences was significantly less in the probiotic group compared to controls.
This association was not found for women with complicated UTIs. Additionally, antibiotic resistance increased in the control group but not
in the probiotic group participants.25
Human Papillomavirus
In a quasi-experimental pilot of L casei Shirota, a probiotic drink was used in participants who had an LGSIL on their Papanicolaou test. 27 The
intervention resulted in significant clearance of HPV lesions, as shown in Table 2. While viral clearance was reduced, it was not statistically
significant.
Length of Follow-up
Follow-up also varied significantly among investigations from one to 11 months. Investigators used various approaches for more long-term
follow-up periods. For example, Bradshaw22 used self-collected swabs returned by mail to the researchers, while Ya20 evaluated long-term
outcomes of BV recurrence through the use of phone calls to collect self-reports.

Adverse Events
Thirteen of the studies reviewed indicated that adverse events monitoring was done,3,14-16,18-22,24-26,31 but 6 of these provided either no
reports or the information was unclear.15,16,19,20,26,32 Two investigators relied on participant self-reports,3,22 while Hemmerling conducted
detailed data collection.14 Overall, there were no significant differences in the incidence of adverse events among probiotic and control

group participants in any of the RCTs that included this analysis. The use of effervescent vaginal tablets led to at least one dropout for
vaginal burning, which could be considered a minor adverse event.32 None of the studies reported serious adverse events.

DISCUSSION
Although clinical practice recommendations were limited by the strength of evidence, probiotic interventions were effective in treatment
and prevention of urogenital infections as alternatives or cotreatments. The synthesized findings presented in Table 2 provide insights that
may be useful to women's health care providers who wish to apply probiotics for treatment and/or prevention of various urogynecologic
infections.

Study Bias and Quality
Tracking of primary and even secondary outcomes compared to study aims was confounded by a lack of precision and clarity in a number of
the studies reviewed. Some of the investigators who conducted RCTs calculated a priori sample sizes by determining the effect size for their
primary outcome variable. Those who did not report such calculations tended to have small sample sizes that precluded statistical analysis
beyond simple frequencies and percentages. More well-controlled studies with sample sizes based on the effect size of the primary
outcome variable are needed to further develop the body of literature.

Limitations
It was challenging to analyze and synthesize study findings because of the heterogeneity in design, methods, and study outcomes, including
those reporting on the same infection. Only 6 of the RCTs reviewed had low risk of bias as assessed by Cochrane Collaboration Risk of Bias
of Randomized Controlled Trials Assessment.34 Our quality ratings allowed us to review all 20 studies for more than risk of bias. However,
the small number of high-quality studies limited determinations about the effectiveness of the interventions in the studies reviewed. More
well-controlled trials that specify a clear purpose and a primary outcome variable that is measurable are needed. It is important for
researchers to describe the probiotic intervention fully and to provide participants with clear and realistic instructions to avoid undue
burden.

Probiotic Interventions
Several investigators provided a specific rationale for the choice of probiotic intervention, some based on in vitro testing of the probiotic
bacteria against particular organisms. The rationale for dosing and/or the treatment duration were not provided in studies. There were
significant variations among the probiotic interventions, such as strain, species, dosage, frequency, routes of administration, and treatment
duration. Even when a common species, such as Lactobacillus acidophilus, was used, the variety of different strains made comparisons
difficult. The properties of one strain may not necessarily be attributed to another. 10 Even when 2 authors reported using the same

commercially available probiotic product, there were variations in ingredient details. The use of commercially available products as
standardized probiotic interventions may allow for the study of the same species, strains, and additional ingredients. These uniform
products hold promise, but their use may be limited by their accessibility in various countries. The variability among studies concerning all
aspects of the probiotic interventions used limited the generalizability and utility of the study outcomes. More research on well-identified
strains tested with larger samples will build a stronger body of knowledge and allow for meta-analyses to inform both research and clinical
practice.

Probiotic Intervention Outcomes
While outcomes varied among studies on probiotics used to treat or prevent the same urogenital infections, a pattern of significant findings
emerged. Table 2 contains a synthesis of significant findings. Authors of a Cochrane Review of probiotics for the treatment of BV, 38 that
included investigations outside of the search years for this systematic review, found that probiotic interventions provided beneficial effects
when given in combination with metronidazole (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.03-0.26) or when combined with
estriol (OR, 0.02; 95% CI, 0.00-0.47).
Although there is no standard, both Reid39 and Andreu40 recommended doses between 109 to 1011 CFUs by any route for probiotic
interventions. In most of the studies, the probiotic intervention was delivered via the vaginal route. Although both oral and vaginal dosing
have been found to be effective in the management of urogenital infections, the ideal route remains unclear. 41
Outcomes that addressed the mechanisms of action of probiotics were reported in several studies. The bacteria in the probiotic
intervention colonized the vagina within 2 to 10 days of administration. 3,14,26 This colonization may sustain beyond the duration of the active
probiotic intervention.3,24 The finding that the intervention decreased 2 proinflammatory cytokines addresses the beneficial immunologic
actions of probiotics.16 In one study, the probiotic intervention acidified the vaginal mucosa more than pH tablets.30 These outcomes may
serve to guide future research as well as clinical practice.
Several of the findings were not statistically significant, yet are clinically relevant. For example, Donders found that a combination product
containing 107 CFU L acidophilus (KS400) plus 0.03 mg estriol was equivalent to metronidazole for the short-term treatment of BV.21 The
consumption of a probiotic milk product containing 8 × 109 CFU L casei Shirota per 2.7-ounce bottle was associated with an increase in HPV
viral clearance.27 In general, HPV infections can spontaneously resolve within 2 years in greater than 79% of individuals, with variations
depending on HPV type, the presence of coinfections with multiple types, and behavioral factors such as smoking. 42 The pilot study finding
that probiotic intervention resulted in significant HPV lesion clearance deserves further attention and study in an RCT. Although
spontaneous LGSIL resolution is possible, the authors of a prospective study identified this occurred in fewer than 20% of participants.43

Lesion clearance is dependent on the same factors that impact viral clearance. 42,43 More well-designed and controlled research studies on
the outcomes of probiotic interventions against HPV infections are needed to verify these findings.
None of the investigators reported any serious adverse events attributable to the probiotic intervention. Adverse events did not differ
significantly between groups in any of the RCTs. Probiotic interventions are generally regarded as safe in healthy populations because
probiotics are not systemically absorbed.44 Active and complete monitoring for adverse events in future investigations will help strengthen
the body of knowledge regarding probiotic safety.

Antibiotic Treatment
The use and timing of antibiotics in relationship to the probiotic intervention varied considerably among studies. The intricacies of
participant instructions for antibiotic versus probiotic timing were only specified in one study. 25 Antibiotics can significantly disrupt the
normal vaginal flora.45 Probiotics must withstand digestion to be effective on mucosal surfaces, such as the vagina.11 If antibiotics and
probiotics were administered simultaneously, the antibiotic could destroy the probiotic bacteria in the gastrointestinal tract.46 Separation of
antibiotics and probiotics doses by 2 to 4 hours is recommended for this reason.46 It is plausible that more investigations would have had
significant findings if antibiotic and probiotic interventions were carefully timed and clearly reported. The prevalent use of antibiotics in
treatment groups may have limited the findings attributable to the probiotic interventions.
Standard antibiotic treatments of infections varied among studies and did not always meet the CDC guidelines for treatment adequacy. For
example, in China, Ling29 used metronidazole once daily for 7 days to treat BV as an active control; however, the CDC recommends twicedaily treatment.2

Intimate Behaviors of Participants
Stark contrasts were found among studies on participant recruitment, inclusion, exclusion, and study restrictions. Exclusions of sexually
active or sexually abstinent women, or women who did or did not use contraception, provide examples of these variations. Although the
vagina is an adaptive ecosystem, unprotected sexual intercourse and menstrual variations lead to fluctuations in the physiology. Douching
and vaginal medications can disrupt vaginal homeostasis.38 As presented in the findings, several investigators conducted data collection on
these variables throughout their investigations. Close control of study variables increases the internal validity in RCTs. However, this analysis
demonstrated the complexity of enrolling female participants and monitoring their intimate behaviors. More research that balances the
need for control with the realities of women's lives will help inform clinical practice.

CONCLUSION
The quality of the studies in this systematic review varied. Although we cannot make substantial clinical practice recommendations based
on the strength of evidence, probiotics may be an alternative or co-treatment of urogenital infections. Women's health care practitioners
can use the available evidence to discuss treatment options with women who wish to avoid antibiotics, or who want to use probiotics to
address their health care needs.
Probiotic interventions were shown to have some efficacy in the treatment and prevention of urogynecologic infections. More wellcontrolled investigations are needed to ensure sufficient sample size for statistical analyses, with consistent inclusion of rationale for
researchers’ choices of probiotics, dosing, procedures, adjunctive antibiotic therapy, and outcome measures whenever possible. In addition,
clarity about the use of randomization, blinding, and other strategies to increase quality and reduce risk of bias is needed in future work.
Given the imperative to reduce antibiotic use to avoid the increasing development of resistance, patients and clinicians need alternative
approaches to treat and prevent common urogenital infections. Probiotic manufacturers might be considered as viable sources of support
for clinical research, as long as these relationships have well-documented boundaries and are clearly documented. Although probiotic
availability has increased, science has to keep pace with generating the necessary knowledge through research to support evidence-based
clinical practice.
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